Mph966    (DrugBank: -)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
228閉塞性細気管支炎1
231α1-アンチトリプシン欠乏症6

228. 閉塞性細気管支炎 [臨床試験数:92,薬物数:125(DrugBank:34),標的遺伝子数:33,標的パスウェイ数:152
Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 92 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02669251
(ClinicalTrials.gov)
April 28, 201629/1/2016Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell TransplantationA Phase 1b/2 Study of Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell TransplantationChronic Graft vs Host Disease;Chronic Graft-Versus-Host-Disease;Bronchiolitis Obliterans SyndromeDrug: MPH966National Cancer Institute (NCI)NULLRecruiting18 Years99 YearsAll34Phase 1/Phase 2United States

231. α1-アンチトリプシン欠乏症 [臨床試験数:83,薬物数:89(DrugBank:16),標的遺伝子数:35,標的パスウェイ数:46
Searched query = "Alpha-1-antitrypsin deficiency", "AATD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 83 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-001309-95-BE
(EUCTR)
06/09/201902/07/2019A Phase 2 placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiencyA Phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 weeks twice daily oral administration of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiency. Alpha-1 antitrypsin deficiency
MedDRA version: 23.1;Level: LLT;Classification code 10001806;Term: Alpha-1 anti-trypsin deficiency;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Alvelestat
Product Code: MPH966
INN or Proposed INN: Alvelestat tosylate
Other descriptive name: ALVELESTAT
Mereo BioPharma 4 LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
182Phase 2United States;Canada;Spain;Poland;Belgium;Denmark;United Kingdom;Sweden
2NCT03679598
(ClinicalTrials.gov)
April 8, 201918/9/2018Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin DeficiencyA First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan DiseaseAlpha-1 Antitrypsin Deficiency (AATD);Pi*ZZ, Pi*SZ, or Pi*Z Null, or Pi*Null Phenotype;Emphysema or COPDDrug: Alvelestat (MPH966);Other: PlaceboUniversity of Alabama at BirminghamNational Institutes of Health (NIH);Mereo BioPharmaRecruiting18 Years80 YearsAll66Phase 2United States
3EUCTR2018-001309-95-GB
(EUCTR)
30/11/201831/07/2018A Phase 2 placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiencyA Phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 weeks twice daily oral administration of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiency. Alpha-1 antitrypsin deficiency
MedDRA version: 20.1;Level: PT;Classification code 10001806;Term: Alpha-1 anti-trypsin deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Alvelestat
Product Code: MPH966
INN or Proposed INN: Alvelestat tosylate
Other descriptive name: ALVELESTAT
Mereo BioPharma 4 LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
182Phase 2United States;Canada;Poland;Belgium;Spain;Denmark;United Kingdom;Sweden
4EUCTR2018-001309-95-DK
(EUCTR)
14/11/201813/09/2018A Phase 2 placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiencyA Phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 weeks twice daily oral administration of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiency. Alpha-1 antitrypsin deficiency
MedDRA version: 20.1;Level: PT;Classification code 10001806;Term: Alpha-1 anti-trypsin deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Mereo BioPharma 4 LtdNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
182 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;Canada;Poland;Spain;Denmark;United Kingdom;Sweden
5NCT03636347
(ClinicalTrials.gov)
October 29, 201820/6/2018A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.A Phase 2, Proof-of-concept, Multicentre, Double-blind, Randomised, Dose-ascending, Sequential Group, Placebo-controlled Study to Evaluate the Mechanistic Effect, Safety, and Tolerability of 12 Weeks Twice Daily Oral Administration of Alvelestat (MPH966) in Participants With Alpha-1 Antitrypsin Deficiency.Alpha 1-Antitrypsin Deficiency;Emphysema;COPDDrug: Placebo Oral Tablet;Drug: Alvelestat oral tablet - dose 1;Drug: Alvelestat oral tablet - dose 2Mereo BioPharmaSyneos HealthRecruiting18 Years75 YearsAll165Phase 2United States;Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2018-001309-95-SE
(EUCTR)
16/10/201806/09/2018A Phase 2 placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiencyA Phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 weeks twice daily oral administration of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiency. Alpha-1 antitrypsin deficiency
MedDRA version: 20.1;Level: PT;Classification code 10001806;Term: Alpha-1 anti-trypsin deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Alvelestat
Product Code: MPH966
INN or Proposed INN: Alvelestat tosylate
Other descriptive name: ALVELESTAT
Mereo BioPharma 4 LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
182Phase 2United States;Canada;Poland;Spain;Denmark;United Kingdom;Sweden